Literature DB >> 31578230

Heterosynaptic GABAB Receptor Function within Feedforward Microcircuits Gates Glutamatergic Transmission in the Nucleus Accumbens Core.

Kevin M Manz1,2, Andrew G Baxley3, Zack Zurawski4, Heidi E Hamm4, Brad A Grueter5,6,7,8.   

Abstract

Complex circuit interactions within the nucleus accumbens (NAc) facilitate goal-directed behavior. Medium spiny neurons (MSNs) mediate NAc output by projecting to functionally divergent brain regions, a property conferred, in part, by the differential projection patterns of D1- and D2 dopamine receptor-expressing MSNs. Glutamatergic afferents to the NAc direct MSN output by recruiting feedforward inhibitory microcircuits comprised of parvalbumin (PV)-expressing interneurons (INs). Furthermore, the GABAB heteroreceptor (GABABR), a Gi/o-coupled G-protein-coupled receptor, is expressed at glutamatergic synapses throughout the mesolimbic network, yet its physiological context and synaptic mechanism within the NAc remains unknown. Here, we explored GABABR function at glutamatergic synapses within PV-IN-embedded microcircuits in the NAc core of male mice. We found that GABABR is expressed presynaptically and recruits a noncanonical signaling mechanism to reduce glutamatergic synaptic efficacy at D1(+) and D1(-) (putative D2) MSN subtypes. Furthermore, PV-INs, a robust source of neuronal GABA in the NAc, heterosynaptically target GABABR to selectively modulate glutamatergic transmission onto D1(+) MSNs. These findings elucidate a new mechanism of feedforward inhibition and refine mechanisms by which GABAB heteroreceptors modulate mesolimbic circuit function.SIGNIFICANCE STATEMENT Glutamatergic transmission in the nucleus accumbens (NAc) critically contributes to goal-directed behaviors. However, intrinsic microcircuit mechanisms governing the integration of these synapses remain largely unknown. Here, we show that parvalbumin-expressing interneurons within feedforward microcircuits heterosynaptically target GABAB heteroreceptors (GABABR) on glutamate terminals. Activation of presynaptically-expressed GABABR decreases glutamatergic synaptic strength by engaging a non-canonical signaling pathway that interferes with vesicular exocytotic release machinery. These findings offer mechanistic insight into the role of GABAB heteroreceptors within reward circuitry, elucidate a novel arm to feedforward inhibitory networks, and inform the growing use of GABABR-selective pharmacotherapy for various motivational disorders, including addiction, major depressive disorder, and autism (Cousins et al., 2002; Kahn et al., 2009; Jacobson et al., 2018; Stoppel et al., 2018; Pisansky et al., 2019).
Copyright © 2019 the authors.

Entities:  

Keywords:  GABAB; feedforward inhibition; nucleus accumbens; parvalbumin interneurons; synaptic plasticity

Mesh:

Substances:

Year:  2019        PMID: 31578230      PMCID: PMC6867813          DOI: 10.1523/JNEUROSCI.1395-19.2019

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  66 in total

1.  Gbetagamma acts at the C terminus of SNAP-25 to mediate presynaptic inhibition.

Authors:  Tatyana Gerachshenko; Trillium Blackmer; Eun-Ja Yoon; Cheryl Bartleson; Heidi E Hamm; Simon Alford
Journal:  Nat Neurosci       Date:  2005-04-17       Impact factor: 24.884

Review 2.  GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings.

Authors:  Michael S Cousins; David C S Roberts; Harriet de Wit
Journal:  Drug Alcohol Depend       Date:  2002-02-01       Impact factor: 4.492

3.  mGlu1 and mGlu5 modulate distinct excitatory inputs to the nucleus accumbens shell.

Authors:  Brandon D Turner; Jerri M Rook; Craig W Lindsley; P Jeffrey Conn; Brad A Grueter
Journal:  Neuropsychopharmacology       Date:  2018-03-27       Impact factor: 7.853

4.  GABA(B) receptors at glutamatergic synapses in the rat striatum.

Authors:  C J Lacey; J Boyes; O Gerlach; L Chen; P J Magill; J P Bolam
Journal:  Neuroscience       Date:  2005-10-14       Impact factor: 3.590

5.  Exogenous and endogenous cannabinoids control synaptic transmission in mice nucleus accumbens.

Authors:  David Robbe; Gerard Alonso; Oliver J Manzoni
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

Review 6.  Endocannabinoid signaling and synaptic function.

Authors:  Pablo E Castillo; Thomas J Younts; Andrés E Chávez; Yuki Hashimotodani
Journal:  Neuron       Date:  2012-10-04       Impact factor: 17.173

7.  GABA transporter 1 tunes GABAergic synaptic transmission at output neurons of the mouse neostriatum.

Authors:  Knut Kirmse; Anton Dvorzhak; Sergei Kirischuk; Rosemarie Grantyn
Journal:  J Physiol       Date:  2008-10-02       Impact factor: 5.182

8.  Nucleus accumbens feedforward inhibition circuit promotes cocaine self-administration.

Authors:  Jun Yu; Yijin Yan; King-Lun Li; Yao Wang; Yanhua H Huang; Nathaniel N Urban; Eric J Nestler; Oliver M Schlüter; Yan Dong
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-25       Impact factor: 11.205

Review 9.  Interneurons. Fast-spiking, parvalbumin⁺ GABAergic interneurons: from cellular design to microcircuit function.

Authors:  Hua Hu; Jian Gan; Peter Jonas
Journal:  Science       Date:  2014-07-31       Impact factor: 47.728

10.  Heterogeneity and Diversity of Striatal GABAergic Interneurons: Update 2018.

Authors:  James M Tepper; Tibor Koós; Osvaldo Ibanez-Sandoval; Fatuel Tecuapetla; Thomas W Faust; Maxime Assous
Journal:  Front Neuroanat       Date:  2018-11-08       Impact factor: 3.856

View more
  14 in total

1.  An endocannabinoid-regulated basolateral amygdala-nucleus accumbens circuit modulates sociability.

Authors:  Oakleigh M Folkes; Rita Báldi; Veronika Kondev; David J Marcus; Nolan D Hartley; Brandon D Turner; Jade K Ayers; Jordan J Baechle; Maya P Misra; Megan Altemus; Carrie A Grueter; Brad A Grueter; Sachin Patel
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

2.  Kappa opioid receptor modulation of excitatory drive onto nucleus accumbens fast-spiking interneurons.

Authors:  Benjamin C Coleman; Kevin M Manz; Brad A Grueter
Journal:  Neuropsychopharmacology       Date:  2021-08-16       Impact factor: 7.853

3.  Cocaine restricts nucleus accumbens feedforward drive through a monoamine-independent mechanism.

Authors:  Kevin M Manz; Benjamin C Coleman; Alexis N Jameson; Dipanwita G Ghose; Sachin Patel; Brad A Grueter
Journal:  Neuropsychopharmacology       Date:  2021-09-20       Impact factor: 7.853

Review 4.  GABAB Receptors and Cognitive Processing in Health and Disease.

Authors:  Styliani Vlachou
Journal:  Curr Top Behav Neurosci       Date:  2022

5.  Noradrenergic Signaling Disengages Feedforward Transmission in the Nucleus Accumbens Shell.

Authors:  Kevin M Manz; Benjamin C Coleman; Carrie A Grueter; Brenda C Shields; Michael R Tadross; Brad A Grueter
Journal:  J Neurosci       Date:  2021-03-18       Impact factor: 6.167

Review 6.  Keeping the Balance: GABAB Receptors in the Developing Brain and Beyond.

Authors:  Davide Bassetti
Journal:  Brain Sci       Date:  2022-03-22

Review 7.  Axo-axonic synapses: Diversity in neural circuit function.

Authors:  Kara K Cover; Brian N Mathur
Journal:  J Comp Neurol       Date:  2020-12-18       Impact factor: 3.028

8.  Synaptic Integration of Subquantal Neurotransmission by Colocalized G Protein-Coupled Receptors in Presynaptic Terminals.

Authors:  Emily Church; Edaeni Hamid; Zack Zurawski; Mariana Potcoava; Eden Flores-Barrera; Adriana Caballero; Kuei Y Tseng; Simon Alford
Journal:  J Neurosci       Date:  2021-12-23       Impact factor: 6.709

9.  Calcium-Permeable AMPA Receptors Promote Endocannabinoid Signaling at Parvalbumin Interneuron Synapses in the Nucleus Accumbens Core.

Authors:  Kevin M Manz; Dipanwita Ghose; Brandon D Turner; Anne Taylor; Jennifer Becker; Carrie A Grueter; Brad A Grueter
Journal:  Cell Rep       Date:  2020-07-28       Impact factor: 9.423

10.  Histamine H3 Receptor Function Biases Excitatory Gain in the Nucleus Accumbens.

Authors:  Kevin M Manz; Jennifer C Becker; Carrie A Grueter; Brad A Grueter
Journal:  Biol Psychiatry       Date:  2020-08-06       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.